Amy Weintrob

Amy Weintrob

Auto-generated profile, based on publicly available information

Amy Weintrob

Medical Center Infectious Diseases Section, Veteran Affairs , Washington, DC

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2016 in Diagnostic Microbiology and Infectious Disease
Verified
Journal Article
Open access
BWBrian K. White
Brian K. White
KMKatrin Mende
Katrin Mende
AWAmy C. Weintrob
Amy C. Weintrob
MBMiriam L. Beckius
Miriam L. Beckius
WZWendy C. Zera
Wendy C. Zera
CMClinton K. Murray
Clinton K. Murray
Data from recent conflicts related to war wounds and obligate anaerobes are limited. We define the epidemiology and antimicrobial susceptibility of obligate anaerobes from Iraq and Afghanistan casualties (6/2009-12/2013), as well as their association with clinical outcomes. Susceptibility against eleven antibiotics (7 classes) was tested. Overall, 59 patients had 119 obligate anaerobes identified (83 were first isolates). Obligate anaerobes were isolated 7-13 days post-injury, primarily from lower extremity wounds (43%), and were largely Bacteroides spp. (42%) and Clostridium spp. (19%). Patients with pelvic wounds were more likely to have Bacteroides spp. and concomitant resistant gram-negative aerobes. Seventy-three percent of isolates were resistant to ≥1 antimicrobials. Bacteroides spp. demonstrated the most resistance (16% of first isolates). Patients with resistant isolates had similar outcomes to those with susceptible strains. Serial recovery of isolates occurred in 15% of patients and was significantly associated with isolation of Bacteroides spp., along with resistant gram-negative aerobes.

1 September 2013 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
PDF file
AGAnuradha Ganesan
Anuradha Ganesan
KCKatrina Crawford
Katrina Crawford
KMKatrin Mende
Katrin Mende
CMClinton K. Murray
Clinton K. Murray
BLBradley Lloyd
Bradley Lloyd
AWAmy C. Weintrob
Amy C. Weintrob
A total of 102 methicillin-resistant Staphylococcus aureus (MRSA) isolates collected from 50 injured service members (June 2009 to December 2011) at U.S. military treatment facilities were analyzed for the conventional mecA gene and mecC homologue by using standard PCR-based methods. The prevalence of the mecC homologue was zero.

1 December 2014 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
DBDana M. Blyth
Dana M. Blyth
KMKatrin Mende
Katrin Mende
AWAmy C. Weintrob
Amy C. Weintrob
MBMiriam L. Beckius
Miriam L. Beckius
WZWendy C. Zera
Wendy C. Zera
CMClinton K. Murray
Clinton K. Murray
Background. Penetrating wounds with environmental contamination are associated with a range of infectious complications, including fungus. This is the first study to examine the epidemiology, resistance patterns, and outcomes of Candida infections and colonization in United States military patients injured in Iraq and Afghanistan. Methods. Clinical information associated with initial unique and serial Candida isolates collected from patients (June 2009–October 2013) through the Trauma Infectious Disease Outcomes Study (TIDOS) was evaluated. Susceptibilities were performed using Sensititre YeastOne (YO-9) plates and interpreted by Clinical Laboratory and Standards Institute (CLSI) and adjusted-European Committee on Antimicrobial Susceptibility Testing (EUCAST) criteria. Results. The analysis included 127 patients with 131 unique Candida isolates, of which 102 were Candida albicans and 29 non-albicans Candida spp. Overall, 99% of patients were male with a median age of 23 and an injury severity score of 22. Injuries were primarily due to blasts (77%) and sustained among personnel serving in Afghanistan (89%). There was a median of 7 days from injury to Candida isolation, and 74 isolates were associated with infection. In the multivariate analysis, non-albicans Candida spp were associated with prior antifungal exposure, blood isolates, and wound isolates (P < .01). Nonsusceptibility by CLSI and EUCAST criteria was associated with non-albicans Candida spp (P < .05). Patients with Candida isolation had a 7.1% mortality rate, compared with 1.4% from the overall TIDOS population. Conclusions. Candida isolation from patients with penetrating war injuries may identify a population at higher risk for death. Prospective studies are needed to determine whether targeted antifungals and surgical management will affect this mortality rate.

1 November 2010 in Vaccine
Verified
Journal Article
Open access
NCNancy F. Crum-Cianflone
Nancy F. Crum-Cianflone
MRMollie Roediger
Mollie Roediger
KHKathy Huppler Hullsiek
Kathy Huppler Hullsiek
AGAnuradha Ganesan
Anuradha Ganesan
MLMichael Landrum
Michael Landrum
EJEdward Janoff
Edward Janoff
Ethnicity may be associated with the incidence of pneumococcal infections and the frequency of protective vaccine responses. Earlier studies have suggested that HIV-infected persons of black ethnicity develop less robust immune responses to pneumococcal vaccination that may relate to their higher incidence of invasive disease. We evaluated the association of ethnicity with capsule-specific antibody responses to pneumococcal revaccination, with either the pneumococcal conjugate (PCV) or polysaccharide (PPV) vaccines among 188 HIV-infected adults. The proportion of the 77 African Americans (AA) and 111 Caucasians with comparable virologic and immunologic parameters who achieved a positive immune response (≥2-fold rise in capsule-specific IgG from baseline with post-vaccination value ≥1 μg/mL for ≥2 of 4 serotypes) at day 60 after revaccination was similar (43% vs. 49%, respectively, p=0.65). Results were also similar when vaccine types (PPV and PCV) were examined separately. Mean changes in log(10) transformed IgG levels from baseline to days 60 and 180 post-vaccination were also not significantly different between AA and Caucasians. In summary, in this ethnically diverse cohort with equal access to care, we did not observe differential antibody responses between AA and Caucasian HIV-infected adults after pneumococcal revaccination.

24 February 2026 in Clinical Infectious Diseases
Verified
Journal Article
Open access
RDRachel Denyer
Rachel Denyer
JTJanet P Tate
Janet P Tate
DBDebra A Benator
Debra A Benator
JLJoseph K Lim
Joseph K Lim
AWAmy Weintrob
Amy Weintrob
Background: One in 3 people with human immunodeficiency virus (HIV-1; PWH) are hepatitis B (HBV) core antibody positive (anti-HBc+) and surface antigen negative (HBsAg−) suggesting prior exposure. HBV reactivation can occur in this group if nucleos(t)ide reverse transcriptase inhibitor antiretrovirals (ARV) active against both HIV and HBV are stopped. We describe HBV reactivation in anti–HBc+/HBsAg− PWH following switch from ARV with HBV activity to ARV without HBV activity. Methods: We identified an at-risk cohort of 5986 anti-HBc+ participants switched from HBV-active to non–HBV-active ARV on or before 31 December 2023 and HBsAg− on the most recent result preceding switch from 63 153 PWH in the Veterans Aging Cohort Study. We defined HBV reactivation as HBV DNA detection or HBsAg+ result at any time following switch. HBV-active ARV included lamivudine, emtricitabine, or tenofovir. Results: Forty (0.67%) anti-HBc+/HBsAg− PWH experienced HBV reactivation after switch to non–HBV-active ARV, with median time to reactivation 8.9 months (interquartile range 5.5–26.7). The rate of HBV reactivation was 25.1 per 10 000 person-years (95% confidence interval [CI], 18.4–34.3). Prespecified subgroup analyses revealed higher rates per 10 000 person-years of HBV reactivation in those HBsAg+ in the remote past with no hepatitis B surface antibody positive (anti-HBs+) result (321; 95% CI, 120–855) versus subgroups never previously HBsAg+ or anti-HBs+ (38.0; 95% CI, 22.9–63.0), or anti-HBs+ but never HBsAg+ (17.4; 95% CI, 11.2–27.0). Conclusions: Overall risk of HBV reactivation appears low after switch from HBV-active to non–HBV-active ARV among anti-HBc+ PWH with no prior HBsAg+. Our results inform provider-patient discussion about HBV reactivation risk when considering ARV switching.

7 February 2024 in Annals of Surgery
Verified
Journal Article
Closed access
ILIra L. Leeds
Ira L. Leeds
LPLesley S. Park
Lesley S. Park
KAKathleen Akgun
Kathleen Akgun
AWAmy Weintrob
Amy Weintrob
AJAmy C. Justice
Amy C. Justice
JKJoseph T. Jr Md King
Joseph T. Jr Md King
Objective: Examine the association between prior SARS-CoV-2 infection, interval from infection to surgery, and adverse surgical outcomes. Summary Background Data: Earlier series have reported worse outcomes for surgery after COVID-19 illness, and these findings have led to routinely deferring surgery seven weeks after infection. Methods: We created a retrospective cohort of patients from the US Veterans Health Administration facilities nationwide, April 2020 to September 2022, undergoing surgical procedures. Primary outcomes were 90-day all-cause mortality and 30-day complications. Within surgical procedure groupings, SARS-CoV-2 infected and uninfected patients were matched in a 1:4 ratio. We categorized patients by 2-week intervals from SARS-CoV-2 positive test to surgery. Hierarchical multilevel multivariable logistic regression models were used to estimate the association between infection to surgery interval versus no infection and primary end points. Results: We identified 82,815 veterans undergoing eligible operations (33% general, 27% orthopedic, 13% urologic, 9% vascular), of whom 16,563 (20%) had laboratory-confirmed SARS-CoV-2 infection before surgery. The multivariable models demonstrated an association between prior SARS-CoV-2 infection and increased 90-day mortality (odds ratio (OR) 1.42, 95% CI: 1.08, 1.86) and complications (OR 1.32, 95% CI: 1.11, 1.57) only for patients having surgery within 14 days of infection. ASA-stratified multivariable models showed that the associations between increased 90-day mortality (OR 1.40, 95% CI: 1.12, 1.75) and complications (OR 1.73, 95% CI: 1.34, 2.24) for patients having surgery within 14 days of infection were confined to those with ASA 4-5. Conclusions: In a contemporary surgical cohort, patients with prior SARS-CoV-2 infection only had increased postoperative mortality or complications when they had surgery within 14 days after the positive test. These findings support revising timing recommendations between surgery and prior SARS-CoV-2 infection.